Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients
NCT ID: NCT04997941
Last Updated: 2024-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
238 participants
INTERVENTIONAL
2021-10-21
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The greater reduction in Ki-67 might be observed in Tamoxifen 40mg arm compared to the Tamoxifen 20mg arm.
Open Label, Phase 2, Randomized with 1:1 allocation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer
NCT00717015
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
NCT05801705
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT06507618
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
NCT03351062
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
NCT01745965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Selective estrogen receptor modulator
* It has been the main endocrine treatment for decades
* Tamoxifen is a major endocrine treatment option, particularly for women who still have a significant ovarian estrogenic activity that cannot be controlled by aromatase inhibitors.
* The prospective clinical trials have shown that tamoxifen 20mg has comparable efficacy against tamoxifen 40mg with fewer toxicities in breast cancer patients. However, most of the trials comparing tamoxifen 20mg and 40mg were done in postmenopausal women.
* Previous studies have suggested that the higher dose of tamoxifen can induce higher serum levels of the drugs, and increasing tamoxifen dose up to 40mg can induce clinical responses in tumors resistant to 20mg of tamoxifen. A recent prospective trial demonstrated that increasing the dose of tamoxifen from 20 mg to 40 mg can compensate for the reduced endoxifen level in intermediate or poor metabolizer tamoxifen metabolizers based on CYP2D6 genotyping.
Ki-67
* Ki-67 antigen, a nuclear antigen, and marker of cell proliferation, is expressed during all cell-cycle phases except for G0, with levels peaking during mitosis.
* Reduction in Ki67 expression is reported to correlate with treatment response to endocrine therapy in ER+ breast cancer, and Ki-67 in short-term neoadjuvant studies has been shown to predict outcome in long-term adjuvant trials.
As the investigators have a higher proportion of young aged, premenopausal breast cancer patients in Korea, the investigators had an opportunity to examine the prognostic impact of young age in breast cancer recurrences and survivals. The institutional database and the Korean nationwide breast cancer registry data have all shown that the poor prognostic effect of a young age was exclusively seen in women with hormone receptor-positive breast cancers, and the effect was potentially due to the resistance to the tamoxifen. As therapeutic options diversify, studies on factors predictive of sensitivity to various endocrine therapies are needed to help select the appropriate treatment for young premenopausal breast cancer patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tamoxifen 40mg
Tamoxifen 20mg b.i.d - Participants will be treated for 14 days.
Tamoxifen Oral Product
Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
Assessment of Ki-67
Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
Surgery
The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
Tamoxifen 20mg
Tamoxifen 10mg b.i.d - Participants will be treated for 14 days.
Tamoxifen Oral Product
Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
Assessment of Ki-67
Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
Surgery
The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tamoxifen Oral Product
Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
Assessment of Ki-67
Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
Surgery
The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Tumor size \>0.5cm on USG
3. Stage I-IIIA BC and planned curative surgery
4. ECOG 0-2
5. Patients with adequate bone marrow function
\- Hemoglobin \> 10 g/dL, Plt \> 100,000/mm3
6. Patients with adequate kidney function
\- serum Cr ≤ 1.4 mg/dL
7. Patients with adequate liver function
* Bilirubin: ≤ 1.5 times of upper normal limit
* AST/ALT: ≤ 1.5 times of upper normal limit
* Alkaline phosphatase: ≤ 1.8 times of upper normal limit
8. Patients who decided to voluntarily participate in this trial with written informed consent
9. Premenopausal women : women who has not removed both ovaries, women who had menses in recent 1 year and FSH level is less than 30mIU/ml
Exclusion Criteria
2. Previous history of chemotherapy or endocrine therapy on contralateral BC for the past 2 years
3. Patients who has distant metastasis
4. Patients who is pregnant or breastfeeding
5. Hormon receptor negative BC
6. Her-2 positive BC
7. Diagnosed pituitary adenoma
8. Women who has endometriosis, unknown vaginal bleeding
9. Inability to understand and willingness to sign a written informed consent
10. Patients with endometriosis or unexplained vaginal bleeding
11. Patients with a history of bleeding constitution, coagulopathy, or thromboembolism
12. Patients who have administered a CYP3A inhibitor or inducer, CYP2D6 inhibitor, etc. within 4 weeks prior to randomization
20 Years
48 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hyeong-Gon Moon
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyeong-Gon Moon
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MORE-T trial
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.